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Abstract: Androgen receptor (AR) mediates the growth of prostate cancer (PCa) throughout its 
course of development, including in abnormal splice variants (AR-SV)-driven advanced stage 
castration-resistant disease. AR stabilization by androgens makes it distinct from other steroid 
receptors, which are typically ubiquitinated and degraded by proteasomes after ligand binding. 
Thus, targeting AR in advanced PCa requires the development of agents that can sustainably 
degrade variant isoforms for effective therapy. Here we report the discovery and characterization 
of potent selective AR degraders (SARDs) that markedly reduce the activity of wildtype and splice 
variant isoforms of AR at sub-micromolar doses. Three SARDs (UT-69, UT-155, and (R)-UT-
155) bind the amino-terminal transcriptional activation domain AF-1, which has not been targeted 
for degradation previously, with two of these SARD (UT-69 and UT-155) also binding the 
carboxy-terminal ligand binding domain. Despite different mechanisms of action, all three SARDs 
degraded wild-type AR and inhibited AR function, exhibiting greater inhibitory potency than the 
approved AR antagonists. Collectively, our results introduce a new candidate class of next-
generation therapeutics to manage advanced PCa. 
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Introduction: The last decade has brought several new drugs for the treatment of advanced 
prostate cancer (PCa). Among these are enzalutamide and apalutamide (ARN-509; NCT0231516), 
which are androgen receptor (AR) antagonists (1,2), as well as abiraterone, whose principal 
mechanism of action is to inhibit an enzyme important for androgen biosynthesis (3). Prolonged 
exposure of PCa cell lines and tumors to these antagonists or to conventional androgen-deprivation 
therapy may result in mutations in the AR ligand binding domain (LBD) or selection for 
cells/clones that contain these mutations and correspondingly, resistance to these molecules (4,5). 
PCa that relapses from medical or surgical castration and/or treatment with AR antagonists, 
clinically termed castration-resistant prostate cancer (CRPC), is typically lethal and effective 
treatment options are limited. Despite the clinical descriptor, CRPC is still dependent on the AR 
for its growth (6,7). 
 
Mechanisms attributed to the development of CRPC and resistance to current treatments include 
over-expression of AR, expression of AR splice variants (AR-SVs) lacking the LBD, mutations in 
the AR in general but particularly the LBD, over-expression of coactivators and other oncogenic 
proteins, adrenal or intra-tumoral androgen synthesis, and activation of intracellular signaling 
pathways, collectively resulting in reactivation of the AR (8-14). In order to provide clinical 
benefit to men with CRPC with disease that is resistant to enzalutamide and/or abiraterone, next-
generation AR-targeted therapeutics ideally should be able to: a) bind to any or multiple domains 
of the AR and inhibit its function or nuclear translocation; b) degrade the AR to prevent any 
inadvertent activation by any of the above mentioned alternate mechanisms; and c) inhibit the 
function of and degrade mutant ARs and AR-SVs.  
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Constitutively active and truncated AR-SVs lacking the LBD contribute to an aggressive 
phenotype of CRPC and render resistance to existing therapeutics (15). Recent studies have 
emphasized the importance of these AR-SVs in some CRPC patients. Patients with AR-V7-
expressing PCa have aggressive disease with shorter progression-free- and overall- survival rates 
and they fail to respond to enzalutamide or abiraterone (16,17). Expression of AR-SVs is an 
indicator of poor prognosis (18,19). Although several studies point to the unresponsiveness of AR-
SV-expressing tumors to existing treatments, other investigations have also identified a cohort of 
AR-SV-expressing patients responding minimally to abiraterone or enzalutamide (20). Regardless 
of whether these variants are drivers of resistant and/or non-resistant disease, it is important to 
treat such evolving forms of CRPC with drugs that also target the AR-SVs. 
Here we describe first-in-class AR antagonists, UT-155 and UT-69, with unique pharmacology 
and chemical structure that selectively bind, inhibit, and degrade the AR and AR-SVs, including 
AR-V7, at nanomolar concentrations. The molecules are more potent than the reference AR 
antagonists tested, including enzalutamide. The advantage of such a degrader is that the reduction 
in AR protein prevents activation by alternate mechanisms, thereby providing a sustained 
treatment option for CRPC.  
Materials and Methods:  
 
Detailed methods for ChIP assay, competitive ligand binding assay, plasmid construction and 
transient transactivation, gene expression, Western blotting, xenograft, nuclear localization, 
microarray, and molecular modeling are provided in the supplementary text. 
 
Reagents.  Androgens, [3H] mibolerone and R1881, were procured from Perkin Elmer (Waltham, 
MA), while lipofectamine, TaqMan PCR primers and fluorescent probes, master mixes, and Cells-
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to-Ct reagents were obtained from Life Technologies (Carlsbad, CA). Dual luciferase assay 
reagents were purchased from Promega (Madison, WI). Dihydrotestosterone (DHT), cell culture 
medium, and charcoal-stripped fetal bovine serum (csFBS) were purchased from Fisher Scientific 
(Waltham, MA). FBS was purchased from Hyclone (San Angelo, TX). AR-N20 and AR-C19 
antibodies were procured from Santa Cruz biotechnology (Santa Cruz, CA). Enzalutamide was 
purchased from MedKoo Biosciences (Chapel Hill, NC). Protein A sepharose was procured from 
GE Healthcare (Pittsburg, PA). MG-132 was purchased from R&D and bortezomib was obtained 
from Selleckchem (Houston, TX). All other reagents used were analytical grade. Structure and 
purity of enzalutamide were confirmed by NMR and mass spectrometry (Supplemental text). 
Cell Culture.  LNCaP, HEK-293, 22RV1, PC-3, and T47D cell lines were procured from the 
American Type Culture Collection (ATCC, Manassas, VA). All of the cells were cultured in 
accordance with the ATCC recommendations. The D567es and AD-1 cell lines were provided by 
Dr. Scott Dehm (University of Minnesota, Minneapolis, MN) (21-23) and LNCaP-abl cell line was 
provided by Dr. Myles Brown (Dana Farber Cancer Institute, Boston, MA) (24). The 
enzalutamide-resistant MR49F (LNCaP-EnzR) cell line was provided by Dr. Martin Gleave 
(University of British Columbia, Vancouver) (25). LNCaP-95 cells were obtained from Dr. Alan 
Meeker (John Hopkins Medical Institute, Baltimore, MD) (26). All cell lines were authenticated 
by short terminal DNA repeat assay (Genetica cell line testing laboratory, Burlington, NC). 
Growth Assay.  Cells were plated at varying densities and in different serum-containing medium 
depending on the cell line in 96-well plates, treated as indicated in the figures, and viability 
measured using sulforhodamine B (SRB) or cell-titer glo assay (Promega, Madison, WI). 
Steady State Fluorescence Spectroscopy. Fluorescence emission spectra were measured for 1 μM 
AR-AF-1 as described previously (27). 
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Nuclear Magnetic Resonance (NMR). AF-1 and various fragments of AF-1 were cloned in 
pGEX4t.1 and pGEX6p.1 vectors. To purify proteins, large scale Luria broth cultures were induced 
with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the O.D. reached 0.6 and 
incubated in a shaker at 25°C for 6 hours. Cells were harvested and lysed in a lysis buffer (50 mM 
Tris pH 7.5, 25-250 mM NaCl, DNase, protease inhibitors, glycerol, EGTA, DTT, and sucrose). 
Protein lysates were purified using glutathione sepharose beads by incubating overnight at 4°C 
with gentle rocking and the purified protein was eluted with elution buffer (lysis buffer without 
DNase) containing 50 mM reduced glutathione. Purified proteins were concentrated using Amicon 
or GE protein concentrators. In cases where GST needed to be cleaved, precision protease was 
used to cleave the GST. The proteins were further purified using FPLC (GE AKTA FPLC) with 
gel filtration (superdex75 10/300 GL) and ion exchange (HiPrep Q FF 16/10) columns. Spectra of 
compounds alone or in combination with purified protein were recorded using 1H NMR (Bruker 
400MHz) in a total volume of 500 μl with 5 μM protein and 200-500 μM small molecule (dissolved 
in deuterated DMSO (d6DMSO)) in 20 mM phosphate buffer made up in 100% deuterated water. 
NMR data were collected using a Bruker AVANCE III 400MHz NMR spectrometer (Bruker 
BioSpin Co. Billerica, MA USA) equipped with a BBO 5 mm NMR probe, and TopSpin 3.0 
software. 1H proton NMR and Saturation-Transfer Difference (STD) experiments were acquired 
using standard pulse sequences in the TopSpin library. Spectral width was set to 16 ppm with H2O 
peak at center. 32K time domain (TD) complex data points and 256 scans were used for 1H proton 
NMR and 1024 scans for STD acquisition. For STD, on- and off-resonance were collected using 
interleaved method. Irradiation frequencies for on- and off-resonance were set at 0.8 ppm and -20 
ppm, respectively. STD was acquired on a sample with ligand compound alone using identical 
settings to make sure the STD signals originated from protein in the protein-compound complex 
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sample. Data were collected at room temperature. Chemical shift was referenced to the H2O peak 
at 4.70 ppm. 
 
Patient specimen collection and PDX creation. Specimens from PCa patients were collected with 
patient consent under a protocol approved by the University of Tennessee Health Science Center 
(UTHSC) Institutional Review Board (IRB) in accordance to the ethical guidelines of the 
Declaration of Helsinki. Briefly, specimens were collected immediately after surgery in RPMI 
medium containing penicillin:streptomycin and fungizone and transported to the laboratory on ice. 
The tissues were minced finely and treated with collagenase for 2 hours. The digested tissues were 
washed with serum-free medium and implanted as 1 mm3 fragments subcutaneously in Nod Scid 
Gamma (NSG) mice. One such PDX, Pr-3001, characterized as CRPC at the time of collection, 
was implanted in castrated mice. All animal studies were conducted under the UTHSC Institutional 
Animal Care and Use Committee (IACUC) approved protocols. 
Statistics. Statistical analysis was performed using JMP-Pro (SAS Institute, Cary, NC), GraphPad 
prism (GraphPad Inc., La Jolla, CA), or SigmaPlot (Systat Inc., San Jose, CA) software. 
Experiments containing two groups were analyzed by simple t-test, while those containing more 
than two groups were analyzed by One Way analysis of variance (ANOVA), followed by Tukey 
post-hoc test.  
 
Results: In our pursuit to develop AR degraders with nanomolar to submicromolar potency, a 
library of small molecules was created utilizing rational drug design based on molecular modeling 
of the LBD. UT-155 and UT-69 (Figure 1A) were selected from this focused library for more 
detailed in vitro and in vivo characterization and mechanistic studies. While most of the efficacy 
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and potency studies were performed with a dose range of 1 pM to 10 μM of the molecules, 
hypotheses-testing proof-of-concept mechanistic studies were performed using 10 μM. 
 
UT-155 and UT-69 effectively antagonize the AR: All molecules in the library were tested in a 
battery of experiments, sequentially, to determine their binding to the LBD (using competitive 
radioligand binding assay) and their antagonistic activity (using transactivation assay). Molecules 
that bound to the AR-LBD and inhibited the AR activity were tested for their ability to decrease 
AR expression (using immunoblotting). 
 
A radioligand binding assay with purified GST-AR-LBD and 1 nM 3H-mibolerone showed that 
while UT-155 and UT-69 bound to the AR-LBD at Ki of 267 nM and 78 nM, respectively (Figure 
1A), known antagonists such as enzalutamide, apalutamide, and galeterone bound with Ki greater 
than 1000 nM (Figure 1A table). The relative binding affinity under experimental conditions 
established in our laboratory indicates approximately an 8-10 fold lower Ki for UT-155 and UT-
69 over enzalutamide (Figure 1A). The Ki for enzalutamide was weaker than previously reported 
in an assay using 18F-FDHT as the agonist (2). While absolute Ki will differ depending on 
experimental conditions, the rank of relative binding affinity should remain the same. 
 
AR transactivation assays were performed using an AR-responsive reporter and wild type AR, 
bicalutamide-resistant W742L, and hydroxyflutamide-resistant T878A AR mutants (28,29). UT-
155 and UT-69 potently inhibited the R1881-induced wildtype AR transactivation with 6-10-fold 
higher potency than enzalutamide (Figure 1B). While UT-155 and UT-69 antagonized both 
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wildtype and mutant ARs comparably, enzalutamide was weaker by two fold with the W742L 
mutant AR relative to the wild type AR (Figure S1A).  
 
To test the receptor specificity, cells were transfected as above except that expression plasmids for 
glucocorticoid receptor (GR), mineralocorticoid receptor (MR), and progesterone receptor (PR) 
and their corresponding agonists were used. Although UT-155 inhibited GR and MR 
transactivation, it did so only at ~10 μM (Figure 1C). UT-155 did however inhibit the PR 
transactivation at concentration comparable to that of the AR (Figure 1C). The same result was 
observed with UT-69 (data not shown). 
 
An early event that controls AR-regulated gene expression in response to agonist is the interaction 
between the N-terminus and the C-terminus of the receptor (N-C interaction) (30). The N-C 
interaction depends on agonistic ligands, and does not occur in the presence of antagonists (30). 
Moreover, this N-C interaction has been shown to be important for AR interaction with chromatin 
(31). Given its critical role in AR function, the SARDs were tested for their ability to alter the N-
C interaction using a mammalian two hybrid assay. Cells were transfected with Gal-4-DBD-AR-
LBD, VP-16-AR-NTD, and Gal-4-RE-LUC, and treated with UT-69 and UT-155. Luciferase 
assays were performed in the cell lysates 24 hours after treatment. Both UT-155 and UT-69 
significantly inhibited the AR N-C interaction with IC50 values comparable to that of their 
antagonistic IC50 (Figure S1B). Importantly, by inhibiting the N-C interaction, the SARDs will 
not only suppress AR transcriptional activity, but may also inhibit AR binding to chromatin.   
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To evaluate whether the observed highly potent AR antagonism translates to inhibition of 
endogenous AR function, UT-155 and UT-69 were tested in LNCaP cells and compared with 
enzalutamide. Treatment of LNCaP cells with UT-155 or UT-69 inhibited 0.1 nM R1881-induced 
PSA and FKBP5 gene expression between 10 and 100 nM with 5-10-fold better potency than 
enzalutamide (Figure 1D). We concurrently tested the effect of UT-155 on the function of 
enzalutamide-resistant (LNCaP-EnzR) F876L-AR (25). LNCaP-EnzR cells were treated with UT-
155 or enzalutamide and the expression of PSA was measured. UT-155, but not enzalutamide, 
inhibited the expression of PSA in LNCaP-EnzR, indicating that the F876L mutant that is resistant 
to enzalutamide is sensitive to UT-155 (Figure 1D right panel).  
 
UT-155 and UT-69 reduce AR expression. Our primary objective was to develop small molecules 
that would bind to the AR LBD and induce receptor degradation at concentrations comparable to 
their binding and antagonistic concentrations. We evaluated the effect of UT-155 and UT-69 on 
AR protein levels via Western blot using N-terminus reactive AR antibody (AR-N20). LNCaP 
cells were treated with UT-155 and UT-69 in the presence of 0.1 nM R1881. Both UT-155 and 
UT-69, but not bicalutamide, reduced the AR expression (Figure 1E). 
 
Competitive antagonism is sufficient for UT-69, but not for UT-155, to inhibit AR function. UT-69 
and UT-155 both compete for binding to the LBD and also reduce AR protein levels at 24 hours 
comparable to the observed decrease in transcriptional activity. To determine whether the 
reduction in expression was required to inhibit AR activity or whether the competitive 
displacement of androgen from the LBD is sufficient to inhibit transcriptional activity, we 
evaluated the effect of the SARDs on the pre-mRNA of NDRG1 and MT2A genes that are rapidly 
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induced by hormones (32). We hypothesized that if SARDs act exclusively by reducing AR levels, 
they will be unable to inhibit the induction of pre-mRNA at 1 or 2 hours as expression of AR is 
not reduced at this time point.  Treatment of LNCaP cells with 0.1 nM R1881 increased the pre-
mRNA of both NDRG1 and MT2A by 1 hour and the increase was sustained at 2 and 24 hours 
(Figure 2A). Both compounds blocked the expression of the pre-mRNA and the mRNA at 24 
hours. While UT-155 failed to inhibit the R1881-dependent increase in the pre-mRNAs observed 
at 1 and 2 hours, UT-69 inhibited the increase even at early time points. These results indicate that 
while competitive antagonism through AR LBD is sufficient for the function of UT-69, 
degradation is necessary for UT-155. These results indicate that UT-155 is a true degrader that 
requires degradation to elicit its effect and competitive binding to the LBD may not have functional 
significance.  
 
The distinction in the regulation of early genes between UT-69 and UT-155 provides additional 
information on the effect of these SARDs on AR N-C interaction. UT-155’s inability to inhibit the 
expression of R1881-induced NDRG-1 and MT2A pre-mRNAs at 1 and 2 hours, the time points 
at which degradation could not be observed, suggests that UT-155 blocks the N-C interaction only 
as a consequence of AR degradation. On the other hand, UT-69’s effect on R1881-induced 
NDRG1 and MT2A pre-mRNAs suggests that UT-69 may not require degradation to block the 
androgen-induced N-C interaction. 
 
Enzalutamide has been reported to prevent binding of AR to chromatin. Thus we asked whether 
the compounds could block R1881-mediated binding to chromatin, LNCaP cells were pre-treated 
with UT-155 or UT-69 for 30 minutes and then with 0.1 nM R1881 for 2 hours. Two and a half 
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hours after the treatment, the cells were fixed to cross-link the protein to DNA. The AR was then 
immunoprecipitated and recruitment to the PSA enhancer was quantified by real time PCR. While 
UT-69 inhibited the recruitment of the AR to the ARE on the PSA enhancer, in concordance with 
the pre-mRNA data, UT-155 failed to inhibit the recruitment of the AR to the ARE on the PSA 
enhancer (Figure 2B). Positive control enzalutamide inhibited the recruitment of AR to PSA 
enhancer (Figure 2B). The experiments shown in the panels were performed at different times and 
hence the fold recruitment of AR in R1881-treated samples is somewhat different between them. 
Although UT-155 can compete with agonist to bind to the purified hormone binding domain 
(Figure 1A), it is possible that the enhanced stability of agonist binding in the full length receptor 
due to N-C interactions (33,34) is sufficient to prevent most of the binding of UT-155 to the LBD 
of the full length receptor. 
 
SARDs degrade the AR: Although Figure 1E showed down-regulation of the AR, which likely is 
through enhanced degradation, there are a number of alternative possibilities including altered 
transcription and/or reduced translation. Figure 3A shows that neither compound reduces 
expression of AR mRNA although expression of FKBP5 is reduced as expected. Figure 3B shows 
that both compounds reduce AR expression much better than galeterone in LNCaP cells. 
Quantification of the blots (values expressed under the lanes) indicates that although over 50% of 
the receptor was degraded at 100 nM, a complete degradation could be observed at 1 µM. UT-155 
also reduces AR expression in AD1 cells (Figure 3C).  
 
Since the AR N-C interaction does not take place in the absence of agonist ligands, the effect of 
UT-69 on AR protein levels in cells grown in stripped serum was determined. As shown in Figure 
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3B, in the absence of ligands, UT-69 reduced the AR protein level below that of the level observed 
in vehicle-treated samples, indicating that SARD-dependent degradation of the AR does not 
require N-C interaction. 
 
Selectivity of AR down-regulation was extensively tested using a range of readouts. First, the 
effect of UT-155 on the protein level of closely related receptors, PR and estrogen receptor (ER) 
was tested in T47D breast cancer cells. Although UT-155 blocked PR-dependent transactivation 
(Figure 1), it had no effect on PR or ER protein levels in T47D cells (Figure 3D). The effect of 
UT-155 on glucocorticoid receptor (GR) protein levels was tested in PC-3 cells transiently 
transfected with an expression construct. While UT-155 inhibited the AR protein under similar 
conditions, it had no effect on GR (Figure S2A). Second, the effect of UT-155 on the fluorescence 
signal emitted by GFP-AR, GFP, or GFP-ANGPTL4 (kind gift from Dr. Lawrence M. Pfeffer, 
University of Tennessee, TN), a protein that has no homology to nuclear receptors, was tested in 
HeLa cells. Treatment of HeLa cells transfected with the GFP-tagged constructs with 10 µM UT-
155 resulted in down-regulation of the GFP signal in GFP-AR-transfected cells, but not in cells 
expressing GFP or GFP-ANGPTL4 (Figure S2B). Additionally, mass spectrometry was 
performed in LNCaP cells treated with vehicle or 10 µM UT-155. The results show that UT-155 
did not inhibit the expression of the proteins identified, other than the AR. Some of the proteins 
identified are shown in Figure S2C. Finally, a study to determine the cross-reactivity of UT-155 
with a panel of kinases demonstrated no significant inhibition of kinase activity. These results 
provide strong evidence for the selectivity of UT-155 to the AR.   
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To determine if the observed UT-155-dependent decrease in the AR level is due to accelerated 
degradation, LNCaP cells were treated with UT-155, the protein synthesis inhibitor 
cycloheximide, or a combination of cycloheximide and UT-155. Treatment of LNCaP cells with 
UT-155 decreased the AR levels by over 50% by 10 hours of treatment initiation. When LNCaP 
cells were treated with a combination of UT-155 and cycloheximide, a decrease in the AR protein 
levels was observed as early as 2-4 hours and expression was essentially lost by 6 hours (Figure 
3E). Figure 3E (graph) shows the reduction in half-life of the AR by UT-155 from 10 hours to 
about 2 hours. Thus, the loss of protein is a result of enhanced degradation. 
 
Phosphorylation due to altered intracellular kinase activity is an important regulator of the AR and 
other receptors (35,36). AR contains at least 10 phosphorylation sites, several of which have been 
shown to play important roles in AR function and in PCa development (35). One of the 
phosphorylation sites, Y267, which is catalyzed by Ack1, has a known role in therapeutic resistance 
in CRPC (35). To determine if activation of this site would render the receptor resistant to SARD-
dependent degradation, a dual approach was adopted. PC-3 cells were transfected with AR or AR 
in combination with a constitutively active Ack1 (CaAck1 (37); a kind gift from Dr. Shelton Earp 
(University of North Carolina, NC), and were treated with R1881 in the presence or absence of 
UT-155. UT-155 down-regulated the AR comparably in the presence or absence of CaAck1 
(Figure S3A). In order to confirm this result, Y267 was mutated to aspartic acid (Y267D) to provide 
a negative charge to this site or to phenylalanine (Y267F) to block phosphorylation of this site. PC-
3 cells were transfected with ARY267D or ARY267F and treated with R1881 in the presence or absence 
of UT-155. UT-155 down-regulated ARs carrying either of these mutants comparable to that of 
the wildtype AR (Figure S3A). This result indicates that phosphorylation at Y267 that confers 
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resistance to therapeutics does not alter the ability of UT-155 to degrade the AR and might provide 
some supporting evidence for our hypothesis that degrading the AR will potentially overcome 
therapeutic resistance.  
 
UT-155 promotes degradation potentially through proteasome pathway. In order to test the 
mechanism of degradation, LNCaP cells were treated with UT-155 in the presence of the 
proteasome inhibitor, bortezomib. Earlier studies have demonstrated that MG-132 inhibits AR 
protein and AR transactivation and blocks AR nuclear translocation (38). This effect was observed 
clearly in cells treated with UT-155 and MG-132 (Figure 3F). To overcome this confounding 
effect on AR expression and localization by MG-132, a clinically used proteasome inhibitor, 
bortezomib (Velcade), was used to determine the role of proteasome pathway in UT-155’s effect 
on AR stability. Earlier studies with bortezomib have not reported any significant effect on AR 
expression or function (39). UT-155 down-regulated the AR protein by 40% in LNCaP cells 
treated for 9 hours. This reduction in AR protein was reversed by bortezomib to the level observed 
in R1881-treated cells (Figure 3F). This result indicates that UT-155 potentially down-regulates 
the AR through the proteasome pathway. To determine the consequence of proteasome inhibition 
on UT-155’s inhibitory effect on AR transactivation, HEK-293 cells were transfected with GRE-
LUC, AR, and CMV-renilla-LUC plasmids and the cells were treated with UT-155 alone or in 
combination with bortezomib in the presence of R1881. UT-155 inhibited the AR transactivation 
induced by 0.1 nM R1881, and this complete inhibition was partially reversed by bortezomib 
(Figure S3B). These results indicate the potential role of the proteasome pathway in UT-155-
dependent AR degradation and functional inhibition.  
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UT-155 promotes degradation of splice-variants of AR. To confirm the capacity of UT-155 to 
induce degradation of AR in different cell lines, we studied the effects of UT-155 in 22RV1 cells, 
which express AR and an AR-SV, AR-V7 (26,40). 22RV1 cells were treated with a dose response 
of UT-155 in charcoal-stripped serum (CSS)-containing medium to represent an androgen-
independent state. UT-155 treatment resulted in the degradation of the AR in 22RV1 cells (Figure 
4A). Remarkably and unexpectedly, UT-155 also degraded AR-V7 in the same experiment.  
  
To validate the results obtained in 22RV1 cells and to ensure that these effects are not cell line 
specific, the ability of UT-155 to promote degradation of the AR-SV was tested in multiple PCa 
cell lines. D567es cells that express AR-SV, AR-v567es, and LNCaP-95 cells that express AR-FL 
and AR-SV were treated with a dose range of UT-155. The cells were harvested 24 hours after 
treatment and a Western blot for the AR and its isoforms was performed (Figure 4A). UT-155 
consistently led to degradation of the AR and its SVs at concentrations ranging between 100 and 
1000 nM, indicating that these SARDs promote degradation of the AR and its SVs under various 
conditions and regardless of the permutation-combination of the AR-FL and SV expression. The 
D567es result suggests a direct interaction of the molecule with the AR-SV. Since the LNCaP-95 
blot was over-exposed to show the effect on AR-SV, which is minimally expressed in this cell 
line, the experiment was repeated with lower protein concentration loaded on to the gel to visualize 
the degradation of the AR-full length (Figure 4A). 
 
We also repeated the experiment shown in Figure 3E in 22RV1 cells to confirm that AR-SV 
down-regulation induced by UT-155 was a result of decreased protein stability. Similar to the 
experimental conditions in LNCaP cells, the 22RV1 cells were treated with UT-155, 
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cycloheximide, or a combination of UT-155 and cycloheximide and the expression of the AR and 
the AR-SV was determined. UT-155 and cycloheximide each decreased the levels of both the AR 
and the AR-SV and degradation was accelerated in the combination treatment (Figure 4B). 
 
Since UT-155 down-regulated the AR-SV protein expressed in various PCa cell lines, we 
performed experiments to determine the effect of UT-155 on the transcriptional activity of two 
constitutively active AR variants, the clinically relevant AR-V7 and a synthetic construct lacking 
the LBD (AR A/BCD). Transactivation assays demonstrated that the activity of AR A/BCD 
(Figure S4A left) was significantly inhibited by UT-155 (Figure S4A right), but not by 
enzalutamide. Similarly, AR-V7-induced transactivation of a UBE2C-promoter luciferase 
construct (kind gift from Dr. Yan Dong, Tulane University (41)) was significantly inhibited by 
UT-155, but not by enzalutamide (Figure S4B). These results suggest that down-regulation of AR-
SVs has significant functional consequences. 
 
Interestingly, AR and AR-SV nuclear localization experiments with UT-155 in enzalutamide-
resistant LNCaP and D567es cells, respectively show that UT-155 inhibits nuclear localization of 
the AR and AR v567es (Figure S5A and S5B), indicating that these molecules have multifaceted 
properties of both degradation and inhibition of nuclear localization. Although v567es in D567es 
cells is localized both in the cytoplasm and in the nucleus, the nuclear localization was reduced 
and the punctate foci observed in the nuclei were reduced significantly in UT-155 treated cells. 
 
UT-155 inhibits AR-SV-dependent gene expression. The effect of UT-155 on AR-V7-dependent 
gene expression was determined in 22RV1 cells. 22RV1 cells plated in charcoal stripped serum-
Research. 
on October 6, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on October 4, 2017; DOI: 10.1158/0008-5472.CAN-17-0976 
18 
 
containing medium were treated with vehicle or 10 μM UT-155 for 48 hours and the expression 
of FKBP5 was measured and normalized to GAPDH. The effect on AR-V7-dependent FKBP5 
expression was inhibited by UT-155, but not by enzalutamide (Figure 4C). 
 
SARDs bind to the AR-AF-1 domain. As UT-155 selectively promotes degradation of the AR-SVs 
without the need for either AR-FL or other partner proteins (cycloheximide experiment), we 
speculated that in addition to its binding to the AR-LBD, UT-155 binds to a region in the N-
terminal domain (NTD). However, the NTD is known to be an intrinsically disordered region of 
the AR with a dearth of reported small molecule ligands, complicating the development of a 
standard competitive binding assay (42,43). Consequently, we sought to demonstrate binding via 
biophysical analyses of ligand in the presence and absence of various AF-1 derived peptides. 
Previous studies have shown that molecules that bind to the NTD region are associated with the 
AF-1 domain that resides between amino acids 141-486 in the NTD region (27).  
 
As a first-step, we evaluated the binding of UT-155 to AF-1 (amino acids 141-486) using steady-
state fluorescence emission spectroscopy. There are two tryptophan residues and up to 12 tyrosine 
residues in the AF-1 domain, providing an opportunity to study the folding properties of this 
domain using intrinsic steady-state fluorescence emission spectra. Excitation at 287 nm excites 
both tyrosine and tryptophan residues (44). This method has been validated as a small molecule 
binding assay and was used to determine binding of small molecules to human serum albumin (45) 
and proteins in saliva (46). To measure the interaction of the individual compounds, steady-state 
fluorescence was measured in the presence of a dose response of UT-155 and the AF-1 protein. 
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UT-155 bound to the AR AF-1 with a Kd of 1.32 μM (Figure 5A). These results were reproduced 
with UT-69 (Figure S6A). 
 
To confirm the results obtained through the fluorescence emission spectra, we employed the 
Biacore method using biotin-labeled AF-1 purified protein. The Biacore assay uses surface 
plasmon resonance (SPR) to measure protein-protein and protein-small molecule interactions (47). 
In this assay, AR AF-1 and 50 nM of UT-155 (Figure S6B left) or UT-69 (Figure S6B right) 
were added to a Biacore chip and SPR was measured. The red and the green lines correspond to 
reference biosensors, while the blue lines are the AF-1-loaded biosensors. As can be clearly seen, 
while UT-155 and UT-69 had no effect on the reference biosensors-loaded chips, UT-155 and UT-
69 shifted the spectra when the chips were loaded with the AF-1 protein. These results confirm the 
interaction of UT-155 and UT-69 with AF-1 as measured by a change in the refraction index in 
the SPR (Figure S6B). 
 
NMR studies confirm the binding of UT-155 to AF-1 between amino acids 244-360. 1H NMR has 
been used in high-throughput screens to detect the binding of small molecules less than 500 Da to 
large proteins greater than 5 KDa (48,49). As opposed to other biophysical methods, it is easier to 
use one dimension NMR to observe changes in line-width or line broadening as a high-throughput 
method to identify the binding of the molecules to proteins and then use Water ligand-observed 
spectroscopy (WaterLOGSY) or Saturation-Transfer Difference (STD) NMR as confirmatory 
methodologies (50). These experiments are based on the fact that NMR observables such as 
linewidths and NOEs vary dramatically between small molecules and large molecules. The 
decreased rotational correlation times upon binding of a small molecule ligand to a heavy target 
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molecule produces an atypical heavy molecule NMR result characterized by broadening and 
weakening of ligand peaks in 1H NMR and negative NOE peaks in the WaterLOGSY as compared 
to the free state. In the absence of any affinity, the small molecule NMR result is obtained (sharp 
peaks in 1H NMR and positive NOEs). This distinction provides the basis for NMR screening 
experiments.  
 
Using these principles, 1H NMR was utilized to confirm the binding of UT-155 to the AF-1 region. 
In the first experiment, UT-155 or enzalutamide (500 μM) was dissolved in deuterated D6DMSO 
and was incubated alone or mixed with 5 μM GST-AF-1 or GST and the binding of the molecules 
to the protein was determined by NMR. While UT-155 alone or in combination with GST exhibited 
sharp peaks revealing the ligand present in the free state, UT-155 in combination with GST-AF-1 
provided broad, diffused, and shorter ligand peaks (Figure 5B; peaks in box) revealing that UT-
155 has affinity for AF-1. Alternatively, the negative control enzalutamide known to bind to the 
LBD failed to exhibit a shorter and broader peak in the presence of AF-1 revealing no affinity for 
AF-1. This result confirms that the UT-155, but not enzalutamide, binds to the AF-1 domain. To 
further confirm the NMR results, we performed WaterLOGSY with UT-155 alone or in 
combination with AF-1. While the UT-155 alone gave a flat signal, UT-155 in combination with 
AF-1 provided a negative signal, characteristic of binding to the protein (Figure 5C).  
 
To determine the precise location within the AF-1 region where UT-155 binds (since the AF-1 
region is between 141 and 486 amino acids), smaller fragments of AF-1 were produced and 
purified (Figure 5D). UT-155 was incubated alone or in combination with GST, GST-AF-1 or 
with the various fragments of the AF-1 region and 1H NMR profiles were obtained. Similar to the 
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results shown in Figure 5B, UT-155 provided a sharp signal by itself and when co-incubated with 
GST, but provided a broad shorter peak when incubated with AF-1 (Figure 5E). Similar to the 
unbound ligand, UT-155 in combination with fragments 1A and 5T gave sharp, tall peaks. 
However, when UT-155 was incubated with fragment 1T, the signal was almost indistinguishable 
from baseline, indicating binding affinity to this region. The profile of UT-155 in combination 
with 1B looked similar to that of the AF-1 profile, confirming a binding to this region. Binding of 
UT-155 to 1T and 1B, but not to 1A, indicates that amino acids 51-211 could be excluded and that 
the binding occurs between amino acids 244 and 360.  
 
Three separate biophysical methods, fluorescence spectra, SPR, and NMR indicate that UT-155 
(and UT-69) have significant affinity for AF-1, suggestive of binding strong enough to mediate 
some of the unique characteristics of the AR antagonists reported herein. 
 
STD-NMR has been used to determine the binding/interaction of a ligand to a receptor. It is based 
on the nuclear Overhauser effect and the principle is based on the ligand resonance signal. An STD 
confirmatory experiment with purified GST-cleaved 1T and UT-155 showed that while the UT-
155 alone had no peaks, UT-155 when combined with 1T showed the peaks corresponding to UT-
155 (Figure S6C). The STD-NMR result served as confirmation for the binding of UT-155 to the 
1T region. 
 
Identification of a SARD that binds to the AF-1, but not to the LBD. The SARDs described here 
have multiple properties. Although UT-155 binds to the isolated LBD, the studies described so far 
demonstrated that degradation is required for UT-155-mediated inhibition of AR activity. To 
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determine the domain that is important for UT-155’s function, we utilized multiple experimental 
approaches, including site-directed mutagenesis and synthesis of (R)-UT-155. 
 
Molecular modeling was performed to determine the amino acids in the AR-LBD with which UT-
155 interacted. UT-155 forms hydrogen bonds with Q711, R752, N705, and L704 (Figure 6A). 
These sites were mutated and a transactivation assay was performed. Mutating these amino acids 
individually compromised the ability of R1881 to activate the AR. While the EC50 of R1881 for 
the wildtype AR was 0.11 nM, the EC50 for the mutant ARs was 7.48 nM for Q711A, 8.72 nM for 
L704A, 15.41 nM for R752L, and 2037 nM for N705A (Figure 6A). Effect of UT-155 on the AR 
mutants transactivation in the presence of 10 nM R1881 was evaluated. The results demonstrated 
that mutating the interacting amino acid residues failed to weaken the antagonistic profile of UT-
155 (Figure 6A). This indicates that although UT-155 interacts with these amino acids, they are 
not critical for its function, which is in concordance with the results obtained with the pre-mRNAs 
(Figure 2A). 
 
UT-155 has a chiral center and the active form at the AR LBD is the S-isomer. We synthesized an 
R-isomer (UT-123 or (R)-UT-155), which is expected to be a weaker LBD binder than the S-
isomer. Radioligand binding assay showed that while the S- isomer bound to the AR LBD with a 
Ki of 267 nM, the R-isomer failed to bind to the AR LBD until 10,000 nM (Figure 6B). We tested 
the effect of (R)-UT-155 on R1881-induced AR transactivation and AR expression. The (R)-UT-
155 was comparable to the (S)-UT-155 in inhibiting AR transactivation and degrading the AR with 
only marginal weakening observed in the antagonistic effect (Figure 6B). (R)-UT-155 also 
inhibited the AR N-C interaction (Figure S1B). These results show that binding to the LBD is not 
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needed for the antagonistic and degradation effects of UT-155. Since (R)-UT-155 failed to bind to 
the LBD yet retained its capacity to induce degradation resulting in loss of activity, we speculated 
that it exclusively binds to the AF-1 domain. We performed an NMR experiment to determine its 
binding to the AF-1. As expected (R)-UT-155 bound to the AF-1 domain (Figure 6C), making it 
the first known AF-1 binding degrader. Further, the effect of (R)-UT-155 on LNCaP cell growth 
and AR-target gene expression was determined. (R)-UT-155 inhibited the proliferation of LNCaP 
cells and the R1881-induced expression of AR-target gene, FKBP5 at concentrations comparable 
to that observed with UT-155 (Figure 6D). 
 
SARDs alter LNCaP transcriptome more potently than enzalutamide: Since the SARDs not only 
antagonize the AR, like enzalutamide, but also degrade the AR, the SARDs might affect the 
transcriptome more robustly than enzalutamide. To test this hypothesis, a microarray study was 
performed in LNCaP cells maintained in charcoal-stripped serum-containing medium for 2 days 
and treated with 10 µM of enzalutamide, UT-155, (R)-UT-155, and UT-69 in the presence of 0.1 
nM R1881 for 24 hours. The results, based on a cut-off of 2-fold change from vehicle-treated 
samples, indicate that UT-155, UT-69, and (R)-UT-155 altered the expression of approximately 
3000 genes, while enzalutamide altered the expression of 927 genes (Figure S7A). The differential 
regulation of gene expression could be due to the weaker response elicited by enzalutamide. A 
similar number of genes were up- and down- regulated by all the molecules. Several AR-regulated 
genes such as KLK3 (PSA), TMPRSS2, NKx3.1 and others were down-regulated in the drug-
treated samples. Although an overlap of about 300 genes between SARDs and enzalutamide 
samples could be observed, the SARDs altered the genes robustly than enzalutamide (Figure S7B). 
The highest change in SARD-treated samples was between 350- and 550- fold, while that in 
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enzalutamide-treated samples was only 22-fold. This suggests that the SARDs may be more 
powerful modifiers of AR function than enzalutamide. Ten genes from the microarray dataset were 
validated by real-time PCR. The results of the real-time PCR validation are in concordance with 
the microarray data (Figure S7C). The gene that was maximally induced by all the SARDs is a 
cellular stress-response transcription factor, activation transcription factor-3 (ATF-3) (51).  
 
The expression data was analyzed using String software (https://string-db.org/). The top canonical 
pathways enriched by the genes regulated by the SARDs and enzalutamide are cellular responses 
to chemical stimuli and stress-related pathways.    
 
UT-155 inhibits AR- and AR-SV -dependent PCa cell proliferation. To determine whether the 
degradation and inhibition of the AR function translates into PCa cell growth inhibition, the effect 
of SARDs on the proliferation of AR-dependent LNCaP, LNCaP-abl, and LNCaP-EnzR cells was 
tested. R1881-induced LNCaP proliferation was completely inhibited by UT-155 in hundreds of 
nanomolar concentration, while enzalutamide inhibited the proliferation at concentrations greater 
than 1 µM (Figure 7A). These results were reproduced in various cell lines, including LNCaP-abl, 
whose growth is androgen independent and resistant to AR antagonists, and in LNCaP-EnzR 
(Figure 7A). UT-155 only modestly inhibited the proliferation of HeLa cells at 30 μM, 
demonstrating its specificity for AR-expressing cells (Figure 7A).  
 
To determine whether the inhibition of the AR-SV function translates into PCa cell growth 
inhibition, the effect of SARDs on the proliferation of AR-FL- and AR-SV-expressing cell lines 
was evaluated. UT-155 inhibited the proliferation of 22RV1 cells at concentrations between 1 and 
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10 μM, while enzalutamide failed to inhibit the proliferation (Figure 7B). These results were 
reproduced in another AR-SV-expressing cell line, LNCaP-95 that expresses AR and AR-SV 
(Figure 7B). The AR-SV transactivation results shown in Figure S4 and the proliferation results 
observed in Figure 7B were also reproduced in R1-D567es cells, where UT-155 inhibited the 
transactivation of v567es and the proliferation of D567es cells (Figure S8B). We also tested the 
SARDs for their ability to inhibit the growth of an AR-negative PCa cell line, PC-3. Although the 
SARDs degrade the ectopically-expressed AR in PC-3 cells, indicating the availability of the 
machinery for AR degradation, the SARDs failed to inhibit the proliferation of PC-3, growth of 
which is not dependent on AR, after 6 days of treatment (Figure S8C), further confirming their 
specificity. A comparison between the LNCaP and PC-3 cell growth in the presence of UT-155 is 
provided in the right panel.  
 
UT-155 inhibits growth of PCa xenografts. The studies described above in vitro models provide 
support that UT-155 inhibits and promotes degradation of both AR-FL and mutant AR. To 
determine the effects in vivo, UT-155 was tested in xenograft models. Because the metabolic 
properties of UT-155 were 5-10 fold better than that of UT-69 and that the half-life of UT-69 in 
liver microsomes was not optimal for in vivo testing (Figure S8D and S8F), we performed in vivo 
studies with UT-155 and not with UT-69. UT-155 inhibited the growth of the LNCaP tumors with 
a 65% tumor growth inhibition (TGI) (Figure 7C). Consistent with the inhibition of tumor volume, 
tumor weights and tumor PSA were also significantly lower by 50-75% in UT-155-treated animals 
(Figure 7C).  
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UT-155 inhibits growth of AR-SV-dependent prostate cancer xenografts. Consistent with the anti-
proliferative effects in vitro, UT-155 significantly inhibited the growth of 22RV1 xenograft by 
53%, while, as expected, enzalutamide had no effect on the growth of the 22RV1 tumors (Figure 
7D). Tumor weights and PSA and the expression of AR and AR-SV were significantly lower in 
UT-155-treated animals (Figure 7D).  
 
In the measurement of drug concentration in the tumors to determine the drug exposure, UT-155 
was extracted from tumors and was detected by mass spectrometry. UT-155 accumulated in the 
tumors and the concentration of 562 nM was above its IC50 concentration (Figure S8F). 
 
Pr-3001 is a patient-derived xenograft (PDX) developed using a specimen from an aggressively 
growing metastatic prostate cancer with Gleason score 10 (5+5). Pr-3001 develops tumors robustly 
and attains approximately 1000 mm3 in less than 2 months. Pr-3001 expresses AR-FL and AR-SV 
and grows in castrated mice. Pr-3001 as a 1 mm3 piece was implanted on the flanks of mice and 
its growth was monitored. When Pr-3001 attained 100-200 mm3, the animals were randomized 
and treated with vehicle or UT-155. Consistent with the observations made in 22RV1 xenografts, 
UT-155 inhibited the growth of Pr-3001 by 40-60% over the course of 14 days (Figure 7E). 
 
Discussion: Using hormone binding, transactivation assays, and Western blotting, we sought to 
identify AR antagonists that induced degradation of AR. Based on our preliminary data, we further 
characterized two compounds, UT-69 and UT-155. These studies yielded some surprising results. 
Whereas UT-69 apparently competes with agonist binding to immediately block transcription with 
a longer term effect of virtually eliminating expression through enhanced degradation, UT-155 
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displays distinct properties. Although UT-155 competes for binding of agonist when measured 
using a purified LBD, it fails to block the initial induction of transcription (Figure 2). This is not 
due to intrinsic agonist activity of the compound because treatment with UT-155 alone yields 
activity comparable to UT-69 alone (Figure 2A, 1 hour). The pre-mRNA data suggest that UT-
155 may not bind to the LBD in native full-length conformation or may bind transiently enough 
(faster off-rate) to not have an impact. The agonist-induced N-C interaction is known to slow the 
off-rate of agonists (33). However, similar to UT-69, UT-155 induces degradation of AR, and thus 
at 24 hours AR activity is eliminated. Remarkably, these compounds inhibit activity and cause 
degradation not only of AR and its point mutants, but also induce degradation of AR-SVs. This 
finding raised the question of whether the compounds also bound to the NTD since the AR-SVs 
lack the LBD. 
 
Due to the lack of a radioligand competitive binding assay, we acknowledge that the bar to 
demonstrate the binding to AF-1 is much higher. Hence, we used multiple independent biophysical 
methods including fluorescence polarization assay, Biacore SPR, and NMR using the AF-1 
domain purified proteins. We also used molecular analytical methods such as Western blots that 
measure the degradation of the AR-SVs that lack LBD, in order to demonstrate the interaction 
with AF-1. All assays demonstrated a direct interaction, although the concentrations of 
components needed to detect an interaction differed due to technical limitations and the 
sensitivities of the techniques. 
 
That binding to the AF-1 promotes the degradation is supported by the sensitivity of the AR-SVs 
to the compounds as well as the finding that (R)-UT-155, which binds only to the AF-1 domain, 
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also induces degradation. Moreover, although UT-155 inhibits PR activity presumably by binding 
to the LBD (Figure 1), it does not induce degradation (Figure 3D) supporting specificity of the 
compounds. 
 
Interest in targeting the NTD or DNA binding of AR has increased since the discovery of the AR-
SVs. Due to the intrinsically disorganized nature of the AR-NTD, its structure has not been 
resolved, making it difficult to develop drugs targeting this domain (52). Any drug that is 
developed for the NTD has to be developed either by screening a large library (27) or by 
serendipity as in our case. EPI-001 and EPI-002, discovered using high-throughput screening have 
been shown to bind to the AR-NTD and inhibit AR function (27). Despite its low affinity 
interaction with the AR-NTD, EPI-001 may have other activities that contribute to its biological 
efficacy, including destabilization of AR mRNA or through peroxisome proliferator and activated 
receptor gamma (PPAR-ɣ) cross-reactivity (53). Another molecule described as being an AR 
degrader is ASC-J9, albeit its direct binding to the AR has not yet been demonstrated and it induces 
degradation at concentrations greater than 10 µM. 
 
Although UT-69 inhibited AR activity directly by inducing degradation, UT-155 was equally 
efficacious at 24 hours and was chosen for the in vivo studies due to its better pharmacokinetic 
(PK) properties. UT-155 reduced growth of tumors in three prostate cancer models (Figure 7) and 
the partial reduction of AR in the 22RV1 tumors suggests that optimization of the compound, 
leading to more extensive reduction in AR would improve efficacy. 
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It should be noted that although UT-155 is more potent than enzalutamide by a log unit in vitro, it 
has to be administered at a much higher dose in vivo than enzalutamide (Figure 7D). UT-155 is a 
first-generation molecule in our library with sub-optimal PK properties. Lead optimization is 
currently being performed to obtain molecules with optimum PK properties, while retaining the 
desired degradation properties. Secondly, enzalutamide’s poor solubility precluded the use of a 
dose comparable to that of UT-155. While degradation and AF-1 binding will be the primary and 
secondary lead optimization criteria, importance will also be given to obtaining an orally 
bioavailable drug with an optimum PK profile. 
 
The salient features of the SARDs have the potential to provide an AR-targeted therapeutic 
approach for patients who have developed enzalutamide-resistant cancers. In addition, degradation 
of the AR and AR-SV will prevent activation by IL-6, PKA, coactivators, intra-tumoral androgens, 
and others. The AR AF-1 domain is the primary domain responsible for coactivator interaction 
(54). Molecules such as UT-155 and UT-69 that bind to the AF-1 domain could confer advantages 
by blocking the AR interaction with coactivators, which is essential for AR function. Considering 
that the AF-1 is the functionally important domain, binding of the SARDs to the LBD is not as 
important as the degradation of the AR and AR-SVs. Leads will be optimized based on the 
selective degradation of the AR and AR-SV obtained by binding to the AF-1 domain. If binding 
to the LBD is imperative to inhibit prostate cancer completely, these SARDs could be combined 
with enzalutamide or other LBD-binding antagonists. 
 
There is an urgent need to develop novel therapeutic approaches for men with advanced prostate 
cancer that are not responsive or become resistant to currently used agents. Rapid and sustained 
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degradation of the AR and AR-SV with a novel mechanism of action suggests that these SARDs 
may provide for such an approach.  
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Figure Legends 
Figure 1: UT-155 and UT-69 inhibit AR function and reduce AR expression. A. Structure of 
UT-155 and UT-69. Ligand binding domain (LBD) binding Ki value is provided below the 
structure. An AR ligand binding assay was performed with GST-tagged purified human AR-LBD 
protein and 1 nM 3H mibolerone. Right table shows the binding Ki comparison between 
molecules. B. UT-155 and UT-69 inhibit AR transactivation. AR transactivation studies were 
performed by transfecting human AR cDNA, GRE-LUC, and CMV-renilla LUC into HEK-293 
cells. Cells were treated 24 hours after transfection with a dose response of antagonists in 
combination with 0.1 nM R1881 and a luciferase assay was performed 48 hours after transfection. 
Values presented are IC50. C. UT-155 cross-reacts with progesterone receptor (PR), but minimally 
with mineralocorticoid receptor (MR) or glucocorticoid receptor (GR). Transactivation was 
performed by transfecting human AR, PR, GR, or MR cDNA, GRE-LUC, and CMV-renilla LUC 
into HEK-293 cells. Cells were treated 24 hours after transfection with indicated doses of UT-155 
in combination with 0.1 nM R1881 (AR), progesterone (PR), dexamethasone (GR), or aldosterone 
(MR) and a luciferase assay was performed 48 hours after transfection. D. UT-155 and UT-69 
potently inhibit the expression of AR-target genes in LNCaP and LNCaP-EnzR cells. LNCaP or 
LNCaP-EnzR cells were maintained in charcoal stripped serum-containing medium for two days 
and treated with vehicle or indicated compounds (UT-155, UT-69, or enzalutamide with doses of 
1, 10, 100, 1000, and 10,000 nM) in the presence of 0.1 nM R1881 for 24 hours. RNA was isolated 
and expression of PSA or FKBP5 was quantified and normalized to GAPDH by real time PCR. E. 
UT-155 and UT-69 reduce AR expression.  LNCaP cells maintained in charcoal stripped serum-
containing medium for 2 days were treated with the indicated doses of UT-155 (left) or 10 µM 
UT-69 or 10 µM bicalutamide (right) in the presence of 0.1 nM R1881 for ~24 hours. Cells were 
harvested and a Western blot for the AR was performed with AR-N20 antibody. Actin was used 
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as a loading control. * significance at p<0.05 from vehicle-treated samples. Enza-enzalutamide; 
Bical-bicalutamide. 
Figure 2. Distinct requirements for UT-155 and UT-69 to inhibit the AR function. A. UT-69, 
but not UT-155, inhibits early induction of NDRG1 and MT2A pre-mRNAs. LNCaP cells 
maintained in charcoal-stripped serum containing medium for 2 days were treated as indicated in 
the figures in triplicates. Cells were pre-treated with 10 µM UT-155 or UT-69 for 30 minutes 
before treatment with 0.1 nM R1881. Cells were harvested, RNA isolated, and the expression of 
various pre-mRNAs and mRNAs was measured at the indicated time-points. Experiments were 
repeated three times to confirm the results. * indicates significance at p<0.05 in combination 
treated samples compared to 0.1 nM R1881-treated samples. B. UT-69, but not UT-155, inhibits 
recruitment of the AR to the androgen response element (ARE). LNCaP cells were serum starved 
for 2 days and were pre-treated with 10 µM UT-69, UT-155, bicalutamide, or enzalutamide for 30 
minutes before treating with 0.1 nM R1881 for 2 hours. DNA-protein complexes were cross-linked 
and AR was immunoprecipitated and its recruitment to the PSA enhancer ARE was measured by 
real time PCR. Experiments were performed at n=3 and the results are expressed as mean ± S.E. 
* indicates significance at p<0.05 in combination-treated samples compared to 0.1 nM R1881- 
treated samples. Bical – bicalutamide; Enza – enzalutamide. 
Figure 3: UT-155 and UT-69 both promote degradation of the AR. A. UT-69 and UT-155 do 
not change AR mRNA levels. LNCaP cells were maintained in charcoal stripped serum-containing 
medium for two days and treated for 24 hours with vehicle, UT-69, or UT-155 (0.001-10,000 nM) 
in the presence of 0.1 nM R1881. RNA was isolated and expression of AR or FKBP5 was 
quantified and normalized to GAPDH by real time PCR. N=3. B. UT-155 and UT-69 decrease 
expression of the AR in LNCaP cells. LNCaP cells maintained in charcoal stripped serum-
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containing medium for 2 days were treated with UT-155 (left), UT-69 (middle), and galeterone 
(right) in the presence or absence of 0.1 nM R1881 for ~24 hours. Cells were harvested and a 
Western blot for the AR was performed with AR-N20 (left and right) and AR-C-19 (middle) 
antibodies. Actin was used as a loading control. AR and actin were densitometrically quantified 
and the level of the AR relative to the level of actin is presented under the blots as fold-change 
from R1881-treated sample. In the middle panel, 1 nM R1881 and 1 µM UT-69 were used. C. UT-
155 decreases expression of AR full length in AD1 cells. AD1 cells expressing AR-FL were 
maintained in charcoal-stripped serum-containing medium for 2 days. Cells were treated for 24 
hours, protein extracted, and Western blot for the AR (AR-N20 antibody) and actin was performed. 
D. UT-155 does not reduce PR and ER expression. T47D cells were plated in growth medium and 
treated with the indicated doses of UT-155. A Western blot for PR, ER, and actin was performed. 
E. UT-155 induces degradation of AR. LNCaP cells were plated in growth medium and treated 
with 10 μM UT-155, 50 μM cycloheximide, or a combination of UT-155 and cycloheximide for 
the indicated times. Cells were harvested, protein extracted, and Western blotted for the AR and 
actin. Results from quantification of the blots (n=3) are provided below. The data were graphed in 
semi-logarithmic scale and best-fit line was created. F. AR degradation by UT-155 could be 
mediated by proteasome pathway. LNCaP cells maintained in charcoal stripped serum-containing 
medium for 2 days were treated with vehicle, 10 µM UT-155 alone or in combination with 10 µM 
MG-132 or 10 µM bortezomib in the presence of 0.1 nM R1881 for 9 hours. Cells were harvested 
and Western blot for AR and GAPDH was performed. The lanes were densitometrically quantified 
and the level of the AR relative to the level of GAPDH is presented under the blots as fold-change 
from R1881-treated sample. Values are expressed as average ± S.E. PR-Progesterone Receptor; 
csFBS-Charcoal-Stripped FBS; ER-Estrogen Receptor.  
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Figure 4. UT-155 promotes degradation of AR-SVs. A. UT-155 reduces expression of AR and 
AR-SV in 22RV1 cells. 22RV1 cells maintained in charcoal-stripped serum-containing medium 
were treated with the indicated doses of UT-155 in the presence of 0.1 nM R1881 for ~24 hours. 
Cells were harvested and Western blot for AR (AR-N20 antibody) and actin was performed. Right 
panels. UT-155 decreases expression of AR-V567es in D567es cells and AR-SV in LNCaP-95 
cells. D567es cells expressing AR-v567es and LNCaP-95 cells expressing AR and AR-SV were 
maintained in growth medium for 2 days. Cells were treated for 24 hours, protein extracted, and a 
Western blot for the AR (AR-N20 antibody) and actin was performed. LNCaP-95 experiment was 
repeated where less protein was loaded on a gel to visualize the degradation of AR full length. B. 
UT-155 induces degradation of AR and AR-SV. 22RV1 cells were plated in growth medium and 
treated with 10 μM UT-155, 50 μM cycloheximide, or a combination of UT-155 and 
cycloheximide for the indicated time-points. Cells were harvested, protein extracted, and Western 
blotted for AR and actin. Results from quantification of the blots are provided as line graphs. The 
data from three experiments were averaged and plotted on a semi-logarithmic graph and a best fit 
line was created. C. UT-155 inhibits AR-target gene expression in 22RV1 cells. 22RV1 cells were 
plated in charcoal stripped serum-containing medium, treated with vehicle or the indicated 
compounds (UT-155 or enzalutamide with 10, 100, 1000, and 10,000 nM) for 48 hours and the 
expression of FKBP5 was measured by real time PCR. * significance from vehicle-treated samples 
at p<0.05. Enza-enzalutamide SV-splice variant; cyclo/cyclohex-cycloheximide. 
Figure 5: UT-155 binds to the AR Activation Function Domain 1 (AF-1) between amino acids 
244 and 360. A. Steady state fluorescence emission spectra for purified AR-AF1 protein. AR-AF-
1 (1 μM) and UT-155 were pre-incubated for at least 30 minutes and steady state fluorescence was 
measured. The emission spectra were all corrected to buffer alone or buffer with UT-155, as 
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necessary. B-E. Nuclear magnetic resonance (NMR) studies confirm the binding of UT-155 to 
AR-AF-1. B. UT-155 or enzalutamide (500 μM) dissolved in deuterated-d6DMSO were either 
added to an NMR tube alone or in combination with 5 μM GST (negative control) or GST-AF-1 
purified protein. The intensity of nuclear spin was measured at different magnetic fields (δ ppm). 
The peaks between 7 and 8 (shown in box) correspond to the aromatic rings of UT-155 and 
enzalutamide. C. WaterLOGSY experiment with UT-155 (200 μM) alone or in combination with 
2 μM purified GST-AR-AF-1 was performed as a confirmation for binding. D. Map of various N-
terminal domain fragments cloned, expressed, and corresponding proteins purified. Purified 
proteins and molecular weight markers are shown (M.Wt. of fragments=M.Wt.+GST M.Wt. of 26 
KDa). E. NMR studies were performed with UT-155 (500 μM) and 5 μM of various N-terminal 
domain fragments as described in panel B. 
Figure 6. Characterization of (R)-UT-155, which binds only to the AF-1. A. Amino acids in 
the AR LBD that interact with UT-155 are important for R1881 transactivation. Molecular 
modeling shows the critical amino acids in the AR-LBD that interact with UT-155. The amino 
acids with which UT-155 forms hydrogen bond were mutated and a transactivation assay was 
performed in HEK-293 cells with R1881 (right). The lower panel shows transactivation assay with 
wildtype and mutant AR with a dose response of UT-155 in combination with 10 nM R1881. B. 
The R isomer of UT-155 inhibits AR transactivation and promotes AR degradation at comparable 
concentrations, despite lack of binding to the LBD. Structures of S and R isomer of UT-155 are 
shown. Binding Ki values are provided under the structures. Western blot and transactivation for 
the AR are shown in the figure. C. (R)-UT-155 binds to the AR AF-1 domain. (R)-UT-155 (500 
μM) dissolved in deuterated-d6DMSO was either added to an NMR tube alone or in combination 
with 5 μM AF-1 purified protein. The intensity of nuclear spin was measured at different magnetic 
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fields (δ ppm). The peaks between 6 and 8 (shown by arrows) correspond to the aromatic rings of 
UT-155. D. (R)-UT-155 inhibits LNCaP cell growth and R1881-induced FKBP5 gene expression. 
LNCaP cells plated in RPMI+1%csFBS medium were treated with a dose response of R-UT-155 
in combination with 0.1 nM R1881. Six days after treatment, with medium changed and re-treated 
after 3 days, an SRB assay was performed to measure the cell viability. Bottom: LNCaP cells were 
maintained in RPMI+1%csFBS medium for 2 days and treated with a dose response of R-UT-155 
in the presence of 0.1 nM R1881 for 24 hours. Cells were harvested, RNA isolated, and expression 
of FKBP5 was measured and normalized to GAPDH. N=3. * indicates significance at p<0.05 in 
combination treated samples compared to 0.1 nM R1881-treated samples. 
Figure 7: UT-155 inhibits prostate cancer cell proliferation. A. UT-155 is a potent inhibitor of 
AR-positive prostate cancer cell proliferation. LNCaP, LNCaP-abl, LNCaP-EnzR, or AR-negative 
Hela cells maintained in charcoal stripped serum containing medium were treated with vehicle or 
the indicated compounds (1 pM-10 μM for LNCaP and 1-30 µM for other cells) in the presence of 
0.1 nM R1881. Cells were re-treated three days later and the cell viability was measured using 
SRB assay after 6 days of treatment. Values are represented as average ± S.E. with n=3. B. UT-
155 is a potent inhibitor of AR-SV-expressing prostate cancer cell proliferation. 22RV1 and 
LNCaP-95 cells were plated in charcoal-stripped serum-containing medium and were treated with 
the indicated concentrations in the absence of R1881 stimulation. SRB assay was performed 6 
days after treatment. UT-155 inhibits growth of AR- and AR-SV-positive prostate cancer 
xenografts. C. UT-155 inhibits growth of LNCaP xenograft. LNCaP cells (5 million/mouse) 
mixed with matrigel were implanted subcutaneously on the flanks of intact NSG mice (n=6-8 
mice/group). Once tumors reached 100-200 mm3, animals were randomized and treated with 
vehicle or UT-155 (100 mg/kg/day s.c.). Tumor volume was measured twice weekly. Tumor 
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weights were recorded at sacrifice. PSA was measured in the protein extracts from the tumors. D. 
UT-155 inhibits growth of 22RV1 xenograft. Xenograft experiment with 22RV1 cells was 
performed as described in panel A in castrated NSG mice (n=6-8 mice/group). Animals were 
treated with vehicle, UT-155 (100 mg/kg/day s.c.), or enzalutamide (30 mg/kg/day s.c.). Tumor 
volume was measured thrice weekly. At sacrifice tumor weights were recorded, protein extracted, 
and Western blot for AR and actin was performed. PSA was measured in the protein extracts from 
the tumors. E. UT-155 inhibits growth of patient-derived xenograft, Pr-3001. Pr-3001 was 
implanted as a 1 mm3 fragment subcutaneously in castrated NSG mice (n=8-10/group) and the 
study was performed as described above. Tumor volume was measured thrice weekly. * 
significance at p<0.05 from vehicle-treated samples. Enza-enzalutamide. Values are expressed as 
average ± S.E. of triplicate values. Enza-enzalutamide. 
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